APPLE 2023 _ ORAL POSTER PRESENTATION

Presentation Date & Time: July 7, 2023, 16:10-17:10

	* YIA			
Presentation No.	Abstract No.	GROUP 1	Presenting Author	Institution/Afilliation
OP-01	275	A Better Prognosis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Tenofovir Compared with Entecavir	Sung Won Chung	University of Ulsan, Korea
0P-02	164	Comparison of the Effects of Entecavir and Tenofovir Disoproxil Fumarate on Recurrence of Hepatocellular Carcinoma after Surgical Resection in Chronic Hepatitis B	Eun Jee Lim	Seoul National University, Korea
OP-03	174	IMbrave050: Adjuvant Atezolizumab+Bevacizumab vs Active Surveillance in Hepatocellular Carcinoma Patients at High Risk of Disease Recurrence Following Resection or Ablation	Han Chu Lee	University of Ulsan, Korea
OP-04	140	Radiological Response as a Predictor of Overall Survival in Locally Advanced Hepatocellular Carcinoma: Analysis of START-FIT Phase II Trial	Chi Leung Chiang	The University of Hong Kong, Hong Kong
OP-05	139	Integrative Multi-Omics Profiling for Resectable Hepatocellular Carcinoma Uncovers Clinically Available Serum Biomarkers to Predict Microvascular Invasion	Incheon Kang	CHA University, Korea
0P-06	*126	Landscape of T-Cell Exhaustion Heterogeneity in Hepatocellular Carcinoma Revealed by Integrating Whole Exome, Transcriptomes, and Single-Cell Sequencing	Soon Kyu Lee	The Catholic University of Korea, Korea

		GROUP 2	Presenting Author	Institution/Afilliation
OP-07	*128	Wild-type Kirsten rat Sarcoma (Kras) Promotes Immune Escape via Suppression of Interferon-mediated Immunity in Hepatocellular Carcinoma	Martina Mang Leng Lei	The Hong Kong Polytechnic University, Hong Kong
OP-08	*82	Differential T-Cell and Monocyte Responses in Hepatocellular Carcinoma Treated with Regorafenib Plus Nivolumab: A Biomarker Analysis of the Phase 2 RENOBATE Trial	Hyung-Don Kim	University of Ulsan, Korea
OP-09	8	Diagnostic Algorithm for Subcentimeter Hepatocellular Carcinoma Using Alpha-fetoprotein and Imaging Features on Gadoxetic Acid-enhanced MRI	Peng Huang	Fudan University, China
OP-10	17	Non-Negligible Differences in Radio-Pathologic Characteristics and Prognosis between Subcentimeter and 1-2 cm Hepatocellular Carcinoma	Peng Huang	Fudan University, China
0P-11	*84	Non-Contrast Abbreviated MRI (NC-aMRI) vs. Contrast-Enhanced (CE-aMRI) for Hepatocellular Carcinoma (HCC) Surveillance among High-Risk Populations - A Meta-Analysis	Soe Thiha Maung	Chulalongkorn University, Thailand
0P-12	226	Machine Learning Classification of Hepatocellular Carcinoma Based on CT Scan Image using Probabilistic Neural Network Algorithm	Rifaldy Fajar	Yogyakarta State University, Indonesia

		GROUP 3	Presenting Author	Institution/Afilliation
0P-13	20	Long-Term Outcomes of Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Multicenter Cohort Study	Heechul Nam	The Catholic University of Korea, Korea
0P-14	98	Translational Hepatectomy for Hepatocellular Carcinoma with Inadequate Future-Liver-Remnant after Portal Vein Ligation in Combination with Apatinib Plus Camrelizumab: A Single-Arm Prospective Pilot Study (PLACES) Compared with ALPPS Cohort	Tao Peng	The First Affiliated Hospital of Guangxi Medical University, China
0P-15	*10	A MRI-Based Prognostic Stratification System for Medical Decision-Making of Multinodular Hepatocellular Carcinoma Patients: Optimization of the Milan Criteria	Fei Wu	Fudan University, China
0P-16	228	Risk Stratification for Early Recurrence after Resection in Patients with Intermediate Stage Hepatocellular Carcinoma	Han Ah Lee	Ewha Womans University, Korea
0P-17	*77	Increased 18F-FDG Uptake of Tumor on PET/CT Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation	Wen-Jing Zheng	Fudan University, China
OP-18	*28	The Impact of Dynamic Changes in Cachexia Index on the Outcomes after Hepatectomy for Hepatocellular Carcinoma	Munetoshi Akaoka	The Jikei University School of Medicine, Japan

		GROUP 4	Presenting Author	Institution/Afilliation
0P-19	160	Four-Year Overall Survival (OS) Update from the Phase 3 HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)	Ghassan K. Abou-Alfa	Cornell University, USA
0P-20	92	Survival Outcomes of Out-Of-Milan Hepatocellular Carcinoma after Yttrium-90 Selective Internal Radiation Therapy in A Single Institution in Asia	Kaina Chen	Singapore General Hospital, Singapore
0P-21	215	Carbon Ion Radiation Therapy as a Local Salvage Treatment for Recurrent or Residual Hepatocellular Carcinoma following Transarterial Chemoembolization	Kei Shibuya	Gunma University Heavy Ion Medical Center, Japan
0P-22	134	Silencing of CircRNA-0033351 Represses Hepatic Stellate Cells Activation and Cytokine Storm Induced by Radiation Therapy for Primary Liver Cancer	Hao Niu	Fudan University, China
0P-23	*61	Performance and Effectiveness of Hepatocellular Carcinoma Screening in Individuals with HBsAg Seropositivity in China: A Multi-Center Population-Based Prospective Study	Hongmei Zeng	National Cancer Center, China
0P-24	154	Soluble Programmed Cell Death-1 as a Predictor of Hepatocellular Carcinoma Development during Nucleoside Analogue Treatment	Masaru Enomoto	Osaka Metropolitan University Graduate School of Medicine, Japan